Sanyou Biopharmaceuticals has raised $44.9M in Series C funding. The Shanghai-based company develops innovative drugs and the AI tools it uses to find them.
Its platform pairs an AI-designed antibody library, which Sanyou calls AI-STAL, with a drug accelerator that combines computational and lab work. The company says it has signed more than 100 collaborative R&D agreements and filed over 180 invention patent applications, with more than 30 granted. It also operates more than 20,000 m² of R&D and GMP facilities and works with over 2,000 pharmaceutical and biotech companies worldwide.
